Advertisement
Collaboration › Details
OSE Immunotherapeutics–Selexis: cell line development, 201611– supply service access to research cell banks from SUREtechnology platform
Period | 2016-11-15 | |
Successor | OSE Immunotherapeutics–Selexis: cell line development, 201705– commercial license for access to RCBs from SUREtechnology platform | |
Partner, 1st | OSE Immunotherapeutics S.A. | |
Today | OSE Pharma S.A. | |
Group | OSE Immunotherapeutics (Group) | |
Partner, 2nd | Selexis S.A. | |
Group | JSR Corporation (Group) | |
Product | SUREtechnology Platform™ (Selexis) | |
Product 2 | Effi-7 (Effimune/OSE Immunotherapeutics/Servier) | |
Person | Bocci, Marco (Selexis 201311– Director European Sales + Business Development before Quintiles) | |
Record changed: 2017-05-30 |
Advertisement
More documents for OSE Immunotherapeutics (Group)
- [1] iOmx Therapeutics AG. (9/5/23). "Press Release: iOmx Therapeutics Appoints Dr. Nils Peter Debus as Chief Business Officer". Martinsried....
- [2] OSE Immunotherapeutics S.A.. (10/7/22). "Press Release: OSE Immunotherapeutics Appoints Nicolas Poirier as Chief Executive Officer". Nantes....
- [3] OSE Immunotherapeutics S.A.. (2/12/20). "Press Release: OSE Immunotherapeutics Announces Artificial Intelligence Antibody Drug Development Collaboration with MAbSilico". Nantes....
- [4] OSE Immunotherapeutics S.A.. (2/7/19). "Press Release: OSE Immunotherapeutics and Servier Announce First Option within Global License Agreement Exercised for further Clinical Development and Potential Commercialisation of OSE-127 in Autoimmune Diseases"....
- [5] Boehringer Ingelheim. (4/4/18). "Press Release: Boehringer Ingelheim and OSE Immunotherapeutics Announce Global Immuno-Oncology Partnership to Develop a Pioneering Checkpoint Inhibitor for the Treatment of Advanced Solid Tumors". Ingelheim & Nantes....
- [6] OSE Immunotherapeutics S.A.. (9/7/17). "Press Release: OSE Immunotherapeutics Reports on First-Half 2017 Financial Results and Provides Update on Clinical Advances of its Product Portfolio". Nantes....
- [7] OSE Immunotherapeutics S.A.. (8/31/17). "Press Release: OSE Immunotherapeutics Announces Presentation at the 19th Annual Rodman & Renshaw Global Investment Conference in New York City, September 10-12, 2017". Nantes....
- [8] OSE Immunotherapeutics S.A.. (7/19/17). "Press Release: OSE Immunotherapeutics Receives €9.2 Million Grant from Bpifrance “Invest in the Future Program” for Development of New Immune Checkpoint Inhibitor OSE-172 (Effi-DEM)". Nantes....
- [9] Selexis S.A.. (5/23/17). "Press Release: Selexis SA and OSE Immunotherapeutics Sign Commercial License Agreement to Further Advance Development of OSE’s Interleukin Receptor 7 Antagonist". Geneva & Nantes....
- [10] OSE Immunotherapeutics S.A.. (2/7/17). "Press Release: OSE Immunotherapeutics to Present Corporate Overview at Upcoming BIO CEO & Investor Conference New York February 13-14, 2017". Nantes....
To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«
Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]
Advertisement
» top